Polydeoxyribonucleotide (PDRN), a low molecular weight DNA mixture (50–1500 bp) conventionally purified from salmon trout (Oncorhynchus mykiss) sperm, is a clinically established tissue regenerative agent acting through adenosine A2A receptor activation and the nucleotide salvage pathway. Its exclusive reliance on animal tissue, however, imposes ethical, supply-chain, and immunogenicity constraints, motivating the search for a biomimetic alternative that reproduces its molecular architecture and bioactivity from a non-animal source. Here we extracted, characterized, and biologically evaluated a plant-derived PDRN from Brassica rapa (BR-PDRN), prepared using a modified CTAB extraction protocol coupled with controlled sonication to replicate the fragment-size profile of clinical-grade PDRN. Spectrophotometric quality control (A260/A280 = 1.95–2.05) and agarose gel electrophoresis confirmed high-purity DNA fragmented to 50–1000 bp, matching salmon-derived PDRN specifications. In NIH3T3 fibroblasts, BR-PDRN (50 µg/mL) significantly increased viability over 3–5 days, accelerated scratch wound closure at 48 h (p < 0.001), and upregulated the wound-healing growth factors VEGF, PDGF-b, KGF, and EGF. In HaCaT keratinocytes, BR-PDRN promoted proliferation and scratch closure at least as effectively as salmon-derived PDRN, with significantly superior late-phase proliferation. By engaging both dermal and epidermal compartments of cutaneous repair, BR-PDRN reproduces—and in the epithelial compartment exceeds—the regenerative activity of its animal-derived counterpart. In differentiated adipocytes, BR-PDRN and salmon-derived PDRN both significantly attenuated adiponectin and leptin secretion, comparably to the anti-obesity agent orlistat, indicating a shared, broader role for PDRN in adipocyte metabolic regulation. Together, these findings establish BR-PDRN as a structurally and functionally biomimetic, scalable, and ethically advantageous alternative to animal-derived PDRN for wound-healing and metabolic applications, exemplifying how plant biosynthetic machinery can be harnessed to recapitulate a clinically validated animal-derived biomaterial.